Linda Yaccarino’s subsequent position after departing X as CEO will probably be one other chief government position at eMed Inhabitants Well being, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting government at NBCUniversal however left to hitch X as CEO for 2 years, the place she managed to have a constructive influence on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared method to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed stated in a press launch that they sought her out for her “simple capacity to barter new partnerships” — it definitely additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed beforehand produced a tech platform that was designed for use with at-home COVID-19 fast antigen assessments, guiding customers via the method of administering these assessments correctly. Now eMed is targeted on GLP-1s, the category of medicine like Ozempic, which can be utilized for each weight administration and therapy of sort 2 diabetes.
“To be a frontrunner in right now’s healthcare market, firms must have a fearless tenacity that enables them to not solely develop, however to even be courageous sufficient to step ahead and redefine a whole business,” Yaccarino stated in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final aim of bettering world healthcare outcomes via our groundbreaking providers and platforms.”
